Vancouver, British Columbia – September 24, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt/Xetra®: ZSB) (the “Company”) announces that it will attend Cosmetic360 in Paris, France, October 15-16, 2015. Cosmetic360 is an innovative trade forum for the cosmetic industry. The conference brings together professionals and industry representatives from all over the world. All facets of the cosmetic industry are represented at the conference including, raw materials, formulation, packaging, testing and analysis, finished products, and distribution. More information on the conference can be found at http://www.cosmetic-360.com/en.
Cosmetic360 provides Sirona Biochem an opportunity to introduce its skin lightening compound SBM-TFC-1067 and cell preservation compound SBM-TFC-837 to industry professionals, international cosmetic company representatives, and other interested parties. The Company will participate in open innovation meetings organized with top cosmetic companies, including L’Oréal, J&J, LVMH, Channel, Boots, and Shiseido. The Company will also be connecting with other companies and representatives in the cosmetic industry at its booth at the conference.
At the conference, Sirona Biochem is entering its cell preservation compound SBM-TFC-837 in the international competition for innovations, “The Cosmetic Victories”. This is a unique competition of projects in the planning or development stage. The jury adjudicating the competition, composed of representatives from top names in the cosmetic industry, will select the most innovative projects and may also become involved in their development.
Dr. Howard Verrico, the Company’s CEO stated, “We are excited to be participating in Cosmetic360. The conference will provide valuable exposure for Sirona and our therapeutic compounds. While we have already been in discussions with several multi-national companies, we hope to promote Sirona to a wider audience at the conference and reach out to new potential partners and contacts.”
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety.
Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.